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Abstract
Objectives.  —  To  determine  the  diagnostic  value  of  contrast-enhanced  ultrasonography,  to  dif-
ferentiate benign  and  malignant  soft-tissue  tumors  and  to  assess  the  feasibility  and  interest  of
modelling enhancement  curves.
Patients  and  methods.  —  This  retrospective  study  includes  118  patients  with  soft-tissue  tumors,
examined  with  ultrasound  after  injection  of  SonoVue®,  a  contrast  product.  The  raw  data  were
treated with  CHI-Q  acquisition  software  to  model  the  enhancement  curves.  We  analyzed  tumor
uptake of  the  contrast  product  visually  and  studied  the  enhancement  curves,  characterized  by
ﬁve parameters:  peak  intensity,  time  to  peak,  mean  transit  time,  initial  slope,  and  area  under
the curve.
Results.  —  There  were  81  benign  and  37  malignant  tumors.  For  a  diagnosis  of  benign  tumor,  the
absence of  contrast  uptake  had  a  sensitivity  of  60%,  a  speciﬁcity  of  68%,  a  positive  predictive
value of  50%  and  a  negative  predictive  of  83%.  Study  of  the  70  curves  obtained  (48  benign
and 22  malignant  tumors)  showed  that  the  parameters  of  area  under  the  curve  (Chi2 =  8.6  and
P <  0.005),  slope  (Chi2 =  8.12  and  P  =  0.004),  and  peak  intensity  (Chi2 =  7.55,  P  =  0.005)  differed
signiﬁcantly  between  the  two  populations.
Conclusion.  —  Absence  of  contrast  uptake  suggests  a  benign  lesion.  The  study  of  enhancement
curves showed  signiﬁcant  differences  between  the  different  tumor  populations.
© 2011  Éditions  françaises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.
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The  characterization  of  soft-tissue  tumors  is  based  essen-
ially  on  morphologic  study  by  MRI  [1,2]. Except  for  some
esions  with  a  speciﬁc  appearance,  such  as  artery-to-vein
alformations  (AVM),  lipomas,  and  elastoﬁbromas,  histo-
ogic  veriﬁcation  is  often  necessary.  The  new  techniques
or  studying  neovascularization,  cellularity,  and  biochem-
cal  characterization  improve  both  tissue  characterization
nd  analysis  of  response  to  treatment  [3—7].
Contrast-enhanced  ultrasonography  (CEUS)  is  one  of
hese  techniques.  Some  recent  studies  have  shown  that  CEUS
an  be  used  to  assess  neoangiogenesis  of  tumors  in  the  liver
8—10], lungs,  thyroid,  ovaries,  and  prostate  [11—14]  and  to
etermine  their  response  to  treatment  very  quickly  [15]. A
roup  at  the  Gustave  Roussy  Institute  (IGR)  has  also  shown
hat  the  use  of  a  perfusion  model  improves  the  analysis  of
ontrast  uptake  and  the  speciﬁcity  of  the  data  [16,17]. Few
tudies,  however,  have  examined  the  characterization  of
eripheral  soft-tissue  tumors  as  benign  or  malignant  [18].
The  aim  of  our  study  was  to  determine  the  diagnostic
alue  of  CEUS  of  peripheral  soft-tissue  tumors  and  the  use
f  software  to  model  enhancement  curves  for  analyzing  con-
rast  uptake.
atients and methods
opulation
his  open,  single-center  retrospective  study  includes  160
atients  seen  between  January  2008  and  June  2010  who
ere  referred  for  ultrasonography  (and  MRI)  to  character-
ze  a  soft-tissue  tumor  suspected  either  of  malignancy  or  of
urther  development  after  it  was  considered  cured  or  stabi-
ized  (desmoid  tumor).  Patients  with  a  tumor  originating  in
one  and  extending  into  soft  tissue  were  not  included.
Patients  were  excluded  when  raw  data  during  ultrasound
cquisition  were  incomplete  (n  =  11),  quality  acquisition  was
t
i
a
Table  1  Histology  of  tumors  (number  of  patients).
Benign  tumor  (n  =  81)  PDC  Malign
Yes  No  
Lipoma 16 1  15  Soft  t
AVM-hemangioma 14 5 9  Und
fusi
Schwannoma,  neuroﬁbroma  10  6  4  Lipo
Desmoid  tumor  8  5  3  Leio
Pseudotumors  and  diverse  9  2  7  Syn
GCT  7  3  4  Der
Isolated  ﬁbrous  T  4  4  0
Myositis  ossiﬁcans  3  0  3  PNST  
Myxoma  3  0  3  Poorly
Plantar  ﬁbromatosis  nodule
(Ledderhose  disease)
2 0  2  Sarcom
pric
Elastoﬁbroma  2  0  2
Mucoid  cyst  1  0  1
Epidermoid  cyst  1  0  1  Lymph
Xanthoma  1  0  1  Metas
GCT: giant cell tumor; PNST: peripheral nerve sheath tumor; T: tumor.F.  Gay  et  al.
oor  (patient  moved,  or  region  of  interest,  [ROI],  could  not
e  determined)  (n  =  26),  or  the  ﬁnal  diagnosis  was  uncer-
ain  (n  =  5).  Forty-two  patients  were  excluded,  mainly  at  the
eginning,  when  we  ﬁrst  started  working  with  this  method.
In  all,  imaging  was  successfully  completed  for  118
atients  (47  men,  71  women,  mean  age:  57.4  years,  range:
8—92  years).
The  ﬁnal  diagnosis  was  based  either  on  histologic  criteria
n  =  78)  or  on  a  characteristic  appearance  with  clinical  and
maging  follow-up  longer  than  6  months  (n  =  40).
Three  subgroups  of  patients  were  identiﬁed:  the  ﬁrst
group  1)  comprised  those  with  benign  tumors  (n  =  81),  group
 the  malignant  primary  soft-tissue  neoplasms  (n  =  23),  and
he  third,  all  of  the  malignant  neoplasms  studied,  including
roup  2  and  all  metastases  and  lymphomas  (n  =  37)  (Table  1).
echnique
he  examinations  were  performed  by  three  persons  qualiﬁed
n  osteoarticular  ultrasound  and  trained  in  the  acquisition
echniques  for  CEUS,  with  an  Aplio  XG  ultrasound  device
Toshiba  Medical,  France)  and  two  probes,  one  superﬁ-
ial  PLT-805AT  (frequency  8  MHz,  ranging  from  5  to  12  MHz)
nd  the  other  a  convex  abdominal  PVT-375BT  (frequency
.5  MHz,  ranging  from  1  to  6  MHz)  for  the  larger  lesions.
he  raw  linear  data  were  acquired  with  CHI-Q  acquisi-
ion  software,  at  frequencies  of  10  MHz,  41  frames  per
econd  in  soft-tissue  mode,  and  2.8  MHz,  39  frames  per  sec-
nd  in  abdominal  mode.  These  data  were  analyzed  on  an
ltraExtend® workstation  (Toshiba  Medical,  France),  with
nhancement  curve  modeling  software  developed  by  the  IGR
patent  PCT/IB2006/003742  described  in  article  [19]).The  ultrasonography  was  initially  performed  in  B  mode
o  identify  the  focal  lesion.  Lesions  were  measured,  local-
zed,  their  characteristics  described  (edges,  echogenicity,
nd  shape),  and  then  their  vascularization  studied  with
ant  tumor  (n  =  37)  PDC
Yes  No
issue  sarcoma  (n  =  19)
ifferentiated,  pleiomorphic,  with
form  cells
11 8  3
sarcoma  5  3  2
myosarcoma  1  1  0
ovial  sarcoma  1  1  0
matoﬁbrosarcoma  1  0  1
1  1  0
 differentiated  malignant  tumor  1  0  1
atoid  carcinoma  and  inﬁltrating
kle  cells
2 2  0
oma  3  2  1
tases  11  8  3
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11Contrast-enhanced  ultrasonography  of  peripheral  soft-tissue
Doppler  color  ﬂow.  This  examination  made  it  possible  to
determine  the  level  of  the  plane  where  the  tumor  appeared
most  tissular.
The  CEUS  was  then  performed  at  the  level  determined  in
B  mode,  with  a  bolus  injection  of  4.8  mL  SonoVue® (Bracco
Imaging,  France)  injected  into  a  vein  in  the  elbow  crease.
The  tubing  was  then  rinsed  with  isotonic  saline  solution.  The
acquisition  was  performed  at  a  low  mechanical  index  in  real
time,  which  enabled  a  quantitative  approach.
The  sequence  of  recording  the  raw  data  of  the  contrast
uptake  process  lasted  at  least  3  minutes  or  until  the  uptake
disappeared  completely.  The  region  with  the  greatest  vas-
cularization  density  was  targeted  as  the  ROI.
Assessment criteria
The  contrast  uptake  was  analyzed  visually,  during  acquisi-
tion,  in  a  binary  mode:  contrast  uptake/no  contrast  uptake.
After  application  of  the  curve  modelling  software,  the
patients  were  classiﬁed  into  four  groups:  contrast  uptake
visible  and  curve  obtained;  no  contrast  uptake  and  no  curve;
contrast  uptake  visible  but  no  curve  modelled;  no  contrast
uptake  but  curve  present.
In  the  group  with  a  curve,  the  modelling  software  fur-
nished  ﬁve  parameters  that  were  analyzed  statistically:
peak  intensity,  time  to  peak,  initial  slope,  mean  transit  time,
and  area  under  the  curve.
The  intensity  of  the  signal  cannot  be  assessed  by  visual
analysis  of  the  curves,  as  the  scale  adapts  to  the  results.
Fig.  1,  which  depicts  the  superposition  of  these  curves,
shows  real  disparities  in  tumor  vascularization.
Statistical analysis
For  the  visual  assessment  of  contrast  uptake,  we  calcu-
lated  the  speciﬁcity,  sensitivity,  positive  predictive  value
(PPV)  and  negative  predictive  values  (NPV)  of  the  absence
of  contrast  uptake  in  a  diagnosis  that  the  tumor  is  benign.
The  enhancement  curve  parameters  were  analyzed  with  the
Kruskal—Wallis  non-parametric  test  for  quantitative  vari-
ables,  to  compare  the  different  groups  of  patients.
Results
Of  118  tumors,  81  were  benign,  23  primary  malignant  neo-
plasms,  11  metastases,  and  three  lymphomas.  The  mean
size  of  the  lesions  in  their  longest  dimension  was  69  mm
(4—220  mm)  in  the  benign  group,  72  mm  (16—320  mm)  in  the
malignant  group,  and  67  mm  in  group  3  (7—320  mm).
Overall,  in  all  four  groups,  45  patients  had  visible  con-
trast  uptake  and  a  curve,  42  neither  visible  contrast  uptake
nor  a  curve,  and  six  visible  contrast  uptake  but  no  curve
(Table  1).  No  curves  were  obtained  from  any  patients  for
whom  contrast  uptake  was  not  visible.
After  the  SonoVue® injection,  contrast  uptake  could  be
seen  in  26/81  benign  tumors  (32.1%)  (Fig.  2),  16/23  primary
malignant  neoplasms  (69.5%)  (Fig.  3),  and  ten  of  14  patients
with  lymphoma  or  a  metastasis  (71.4%).
When  we  took  all  the  lesions  into  account,  the  absence
of  contrast  uptake  had  a  sensitivity  of  70%,  a  speciﬁcity  of
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Figure 1. Comparative curves at the same scale of four tumors with different contrast uptake. a: Dedifferentiated liposarcoma; b: Synovial
sarcoma; c: Schwannoma; d: Desmoid tumor; e: Summary graph of curves.
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(8%,  a  PPV  of  50%,  and  a  NPV  of  83%  for  a  diagnosis  that  the
esion  was  benign.
The  parametric  study  was  performed  from  69  curves
btained  with  the  modelling  software  (60%  of  cases),  that  is,
7/81  in  group  1  and  22/37  in  group  3  (including  14  in  group
).  Table  2  summarizes  these  results  and  Table  3  presents
heir  statistical  analysis.
The  area  under  the  curve  was  the  most  discriminating
easure,  with  a  Chi2 =  8.61  and  P  <  0.005  for  discriminating
P
a
(
denign  from  malignant  tumors  among  all  the  lesions  studied
nd  Chi2 =  7.71  (P  =  0.005)  when  metastases  and  lymphomas
ere  excluded.
Two  other  indicators  emerged  as  signiﬁcant:  slope
Chi2 =  8.12,  P  =  0.004)  and  peak  intensity  (Chi2 =  7;  55,
 =  0.005).  On  the  other  hand,  study  of  time  to  peak
nd  mean  transit  time  showed  no  exploitable  variability
Fig.  4).  Nor  was  it  possible  to  deﬁne  a cut-off  point  for
istinguishing  benign  from  malignant  tumors  because  the
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Table  3  Kruskal-Wallis  Chi2.
Benign/malignant  Benign/malignant  +  metastases  +  lymphoma
Kruskal-Wallis  Chi2 P  value  Kruskal-Wallis  Chi2 P  value
Slope 7.5561  0.005981  8.121  0.004375
Peak  intensity  7.4845  0.006223  7.5581  0.005974
Time  to  peak  0.5697  0.4504  0.2788  0.5975
Mean  transit  time 1.059  0.3034  0.1078  0.7426
Area  under  the  curve 7.7196  0.00546
Figure 2. Patient with a dedifferentiated liposarcoma of the thigh. a, b
ultrasonography at 22 and 53 s; g: Raw data in red, model of the curve in3  8.6185  0.003328
, c: MRI and perfusion; d: Ultrasonography; e, f: Contrast-enhanced
 green, table of parameter calculation.
42  F.  Gay  et  al.
Figure 3. Leg schwannoma. a: MRI; b: Contrast-enhanced ultrasonography at 1 min 13; c, d: Perfusion CT; e: Parameter calculation table,
model of the curve.
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Figure 4. Box plot. Upper and lower edges of the box: ﬁrst and third quartile. a: Peak intensity; b: Time to peak; c: Slope; d: Mean time
transit; e: Area under the curve. Logarithmic scale used in the vertical axis: : median: long horizontal line within the rectangular
box. + : medium. o: minimum and maximum.
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ut-off  values  varied  too  much  in  relation  to  the  number  of
ubjects.
iscussion
haracterization  of  the  tumor  remains  a  major  issue  in
he  management  of  soft-tissue  tumors.  Some  lesions  with
n  appearance  on  imaging  characteristic  of  benign  tumors
lipoma,  AVM,  elastoﬁbroma,  or  mucoid  cyst)  may  not  jus-
ify  a  biopsy.  Inversely,  any  tumor  that  is  either  malignant
r  uncertain  requires  histologic  veriﬁcation.  Nonetheless,
espite  the  progress  in  techniques  of  biopsy,  guidance,
nd  cytologic  and  histologic  analyses,  some  biopsies  remain
egative  and  create  the  risk  of  erroneous  diagnoses  and
omplications.  Moreover,  it  is  not  unusual  to  observe  that
ome  biopsies  follow  an  extra  compartmental  route  that
odiﬁes  the  prognosis  and  management  of  malignant  neo-
lasms.  For  these  reasons,  numerous  authors  underline  that
hese  procedures  should  be  performed  only  in  specialized
enters  where  the  type  and  route  of  biopsy  are  decided
y  a  multidisciplinary  decision  treatment  committee
20—22].
It  is  nonetheless  true  that  the  improvement  of  the
ools  for  characterizing  benign  lesions  or  for  differentiat-
ng  benign  and  malignant  tumors  should  make  it  possible
o  avoid  some  biopsies  and  facilitate  management.  Neoan-
iogenesis  is  an  independent  and  quantiﬁable  criterion  of
alignancy  [23,24],  widely  used  in  MRI  and  still  more
romisingly  in  CT  [25—27]. Nonetheless,  perfusion  studies
ack  speciﬁcity.  In  CT,  as  in  MRI,  contrast  products  diffuse
hrough  the  tumor’s  vascular  sector  and  then  its  intersti-
ial  tissue.  In  malignant  neoplasms,  microvascularization,
timulated  by  angiogenic  factors,  is  formed  by  abnormal
icrovessels  that  are  fragile  and  extremely  permeable,  gen-
rating  in  a  characteristic  fashion  a  contrast  uptake  that
s  rapid,  intense,  and  heterogeneous  with  small,  irregular,
narchic  vessels.  These  abnormalities  may  be  missing  or  not
etectable  with  current  techniques  [3,28—30].
CEUS  is  different  from  Doppler  ultrasound  because  it
etects  the  microcirculation  better.  It  is  different  from  MRI
r  CT  for  several  reasons:
enhancement  in  CEUS  reﬂects  the  vascular  portion  of  neo-
vascularization,  without  passing  through  the  interstitial
sector,  unlike  contrast  products  in  CT  and  MRI,  where  a
portion  of  the  tumor  enhancement  is  due  to  the  pres-
ence  of  contrast  product  in  the  interstitial  area.  With  CT
and  MRI,  the  speed  and  amplitude  of  the  enhancement
associated  with  exchanges  between  the  plasma  and  the
interstitial  tissue  depend  respectively  on  capillary  per-
meability  and  on  the  dilution  volume  in  the  interstitial
tissue;
although  the  spatial  analysis  in  the  plane  is  well  corre-
lated  with  the  MRI  [31], its  temporal  resolution  is  much
better  than  those  of  CT  and  especially  MRI.  Ultrasonogra-
phy  obtains  12  to  24  images/s  and  records  the  raw  linear
data  at  four  images  per  second.  In  comparison,  perfusion
CT  can  obtain  a  measurement  every  0.3  to  5  s,  and  MRI
generally  furnishes  images  at  a  still  greater  interval.  The
initial  phase,  which  reﬂects  perfusion  and  blood  volume,
is  very  brief,  on  the  order  of  10  to  20  s  and  thus  theoret-
ically  requires  a  temporal  resolution  on  the  order  of  one
i
n
b
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image  per  second.  The  mathematical  models  that  adapt
to  poorer  temporal  resolution  have  numerous  limitations
[2];
ﬁnally,  like  CT  but  unlike  MRI,  in  CEUS  the  intensity  of  the
signal  is  proportional  to  the  concentration  of  the  contrast
product.
For  all  of  these  reasons,  the  results  obtained  with  CEUS
iffer  from  those  obtained  with  MRI  or  CT.  Our  study  shows
hat  modelling  the  contrast  uptake  is  possible  in  60%  of
ases:  the  area  under  the  enhancement  curve  is  probably
 good  reﬂection  of  neoangiogenesis  although  it  does  not
ppear  sufﬁciently  discriminant.  In  the  absence  of  the  curve,
inary  analysis  (contrast  uptake  or  none)  remains  possible.
he  absence  of  contrast  uptake  is  a  good  negative  predic-
ive  factor  for  malignancy  but  its  speciﬁcity  is  insufﬁcient.
rom  a  practical  point  of  view,  visual  analysis  of  the  contrast
ptake  represents  the  ﬁrst  stage.  That  is,  the  absence  of
ontrast  uptake  has  a  strong  NPV  for  malignancy  and  makes
ny  attempt  at  modelling  futile.
Several  studies  have  shown  the  interest  of  this  tech-
ique  in  other  ﬁelds  of  application.  In  the  multicenter  study
eported  by  H  Trillaud,  CEUS  was  more  effective  than  either
T  or  MRI  in  characterizing  focal  hepatic  lesions  [32]. It
nables  an  earlier  determination  of  the  efﬁcacy  of  antian-
iogenic  treatment  than  does  either  CT  or  MRI  because
emodynamic  modiﬁcations  occur  several  days  before  the
umor  actually  shrinks  [17,19]. Finally,  the  multicenter
tudy  reported  by  F  Tranquard  demonstrates  the  excellent
cceptability  and  economic  beneﬁts  of  CEUS  compared  to
ither  CT  or  MRI  in  the  diagnosis  of  nodular  hepatic  lesions
33].
This  technique  has  several  limitations.  As  for  any  rela-
ively  new  method,  it  comes  with  a  speciﬁc  learning  curve,
s  shown  by  the  exclusion  of  our  earliest  patients.  It  requires
n  appropriate  ultrasound  device  with  software  for  curve
odelling.  This  equipment  is  becoming  more  widely  used,
nd  numerous  devices  today  have  built-in  quantiﬁcation
oftware,  although  the  use  of  an  external  workstation  facili-
ates  data  treatment.  It  is  necessary  to  choose  carefully  the
lane  passing  through  the  zone  most  representative  of  the
umor,  which  probably  makes  CEUS  a  second-line  technique,
ossibly  after  CT  or  MRI.  A  double  injection  is  also  conceiv-
ble,  with  a  ﬁrst  acquisition  of  the  entire  tumor  to  identify
he  most  vascularized  area.
This  study  involves  several  biases.  There  is  a selection
ias  since  it  is  a retrospective  study  and  numerous  benign
esions  did  not  beneﬁt  from  this  technique.  Accordingly,
he  proportion  of  malignant  neoplasms  to  benign  tumors
s  higher  than  in  most  series  but  nonetheless  lower  than
hat  seen  in  some  oncology  centers  [34—36]. The  ratio  thus
emains  acceptable.  The  second  bias  involves  the  visual  and
herefore  subjective  choice  of  the  ROI.  Unlike  the  stud-
es  of  treatment  follow-up,  where  the  ROI  must  include
he  entire  tumor  [19,37], it  is  preferable  in  characterizing
esions  to  avoid  areas  of  necrosis  or  of  myxoid  degeneration.
onetheless,  positioning  the  ROI  can  be  difﬁcult  when  only
he  capsule  or  extreme  periphery  is  vascularized.  Finally,  it
s  probable  that  the  curves  obtained  for  the  tumors  that  did
ot  take  up  the  contrast  product  reﬂect  the  noise  of  tissue
ackscatter  rather  than  any  real  neoangiogenesis.  We  have
hosen  to  conserve  these  curves  as  long  as  the  data  appeared
 tum
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consistent  because  noise  is  inherent  in  the  technique  and
therefore  present  in  all  the  curves.
Finally,  the  results  probably  depend  on  the  equipment
and  technology  used,  but  these  are  currently  the  only  ones
available  on  the  market.
Conclusion
CEUS  is  a  technique  easily  applicable  to  soft-tissue  tumors.  It
is  potentially  interesting  for  characterizing  them.  This  inter-
est  is  strengthened  by  the  use  of  software  for  modelling  the
kinetics  of  the  contrast  uptake.  A  prospective  study  com-
paring  the  relative  utility  of  MRI  and  ultrasonography  for
this  subject  and  assessing  the  correlation  of  the  results  as  a
function  of  the  tumor  volume  is  currently  underway  in  our
department.
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